Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 81.2%

Neg 0% Neu 0% Pos 81.2%

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.